SCHEMBL1332998

SCHEMBL1332998

[CH2]C(CC)c1ncccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.41
NOS1 P29475 1/20 0.41
NOS2 P35228 1/20 0.41
CYP2D6 P10635 2/20 0.35
HRH1 P35367 1/20 0.35
KCNH2 Q12809 1/20 0.35
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 2/20 0.34
PLAU P00749 1/20 0.34
RAB9A P51151 1/20 0.34
CYP2A6 P11509 1/20 0.34
FDPS P14324 3/20 0.34
MAPT P10636 3/20 0.34
GAA P10253 1/20 0.34
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HSP90AA1 P07900 1/20 0.32
IDH1 O75874 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26381413 0.80 NOS3 (0.43) NOS3NOS1NOS2CYP2D6HRH1
SCHEMBL1334164 0.79 HDAC8 (0.30)
SCHEMBL1332464 0.79 TRPM8 (0.33) NPC1RAB9ALMNA
SCHEMBL1332523 0.79 ALDH1A1 (0.41) KDM4ENPC1RAB9AMAPTGAA
SCHEMBL1331826 0.79 CYP2D6 (0.36) CYP2D6HRH1NPC1RAB9ACYP2C19
SCHEMBL1333777 0.79 CYP2D6 (0.36) CYP2D6HRH1KCNH2KDM4ECTNNB1
SCHEMBL11888061 0.78 NOS3 (0.42) NOS3NOS1NOS2CYP2D6HRH1
SCHEMBL10873419 0.78 NOS3 (0.42) NOS3NOS1NOS2CYP2D6HRH1
SCHEMBL895915 0.75 SMN1; SMN2 (0.41) NOS3NOS1NOS2CYP2D6NPC1
SCHEMBL1331823 0.75 HPGD (0.45) CYP2D6KDM4ENPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281885-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN PURDUE PHARMA L.P. (US) 2011-11-17 US disclosed
US-7799786-B2 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. (US) 2010-09-21 US disclosed
US-20080153835-A1 Therapeutic agents useful for treating pain EURO-CELTIQUE S.A. 2008-06-26 US disclosed
EP-1556354-B1 THERAPEUTIC PIPERAZINE DERIVATES USEFUL FOR TREATING PAIN EURO CELTIQUE SA (LU) 2008-01-23 EP disclosed
US-7279493-B2 cyanoiminopiperazines which inhibit vanilloid receptor 1 function in a cell EURO-CELTIQUE S.A. 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080153835-A1 Therapeutic agents useful for treating pain CHRM2, CHRM1, MC1R NOS3 1608/4885NOS1 2171/4885NOS2 1752/4885
US-20110281885-A1 THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN CHRM2, CHRM1, MC1R NOS3 1608/4885NOS1 2171/4885NOS2 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.